- Actavis EVP Gudbjorg Edda Eggertsdottir appointed deputy CEO -
- New Actavis chief complements his team with internal promotions -

Actavis has appointed Gudbjorg Edda Eggertsdottir, Deputy CEO. At the same time, Valur Ragnarsson has been appointed Executive Vice President of Third-party sales; and Doug Boothe, CEO of Actavis United States.

Valur will join the Group’s Executive board with immediate effect, while Gudbjorg Edda and Doug already are executive board members.

Gudbjorg Edda Eggertsdottir joined Actavis following the Company’s merger with Delta, where she had been Deputy CEO and Managing Director of Exports and Development since 1999. She was appointed Actavis’ Chief Executive of Third-party sales in 2002.
Gudbjorg Edda has an MSc degree in Pharmacy and has worked in the pharmaceuticals industry since 1976.

Valur Ragnarsson joined Medis, Actavis’ Third-party sales division, in 2001 and was appointed Managing Director in October 2003. Earlier in his career he held the posts of Marketing Manager of Lundbeck in Iceland and later as Marketing Manager of Aventis.
Valur is a pharmacist by education and has worked within the pharmaceutical industry since 1988.

Doug Boothe joined Actavis through the acquisition of Alpharma in 2005. During the past four years he has held a variety of management positions within the company, the most recent of which was Executive Vice President U.S. Commercial and Administration. Prior to joining Actavis, Doug worked for General Electric, Mars & Co Consulting, Xerox Corporation, and Pharmacia. Doug holds a B.S. in Engineering from Princeton University and an MBA from Wharton School of Business.

Actavis announced changes at the helm last week, when Robert Wessman stepped down. Commenting on the senior appointments today, succeeding
CEO Sigurdur Oli Olafsson said:
“We have a world-class management team with global expertise. We fully intend to continue the remarkable Actavis growth story but our main focus this year will remain on internal growth.”

New Actavis deputy CEO Gudbjorg Edda Eggertsdottir, said:
“The best business leaders build teams that remain flexible, teams that continue to perform even after their departure. Through the changes in ownership last year, it was business as usual at Actavis. Following the departure of Robert Wessman, it will continue to be business as usual at Actavis. We have an incredibly committed team that will continue to provide quick to market, low cost, high quality pharmaceuticals around the global marketplace.”